Silence Therapeutics plc
SLNPharmaceutical Preparations · Avg daily volume 2.8M · fiscal year ends Dec$19.58+10.90+125.58%Volume 71.9M+2,437% vs avg
10-day20-day50-day200-dayRS line vs S&P 500▲ earnings filed, EPS vs a year agoQ3 EPS due in ~17 days
2026-10-19O 19.59 H 19.61 L 19.56 C 19.58 (+125.58%)Vol 71.9M10 10.4120 10.7450 12.46200 8.43RS line 2.555RS rating 99
| FY (Dec) | EPS $ | Chg | High | Low |
|---|---|---|---|---|
| 2022 | -0.52 | – | – | – |
| 2023 | -0.49 | +6% | – | – |
| 2024 | -0.33 | +33% | 28 | 6 |
| 2025 | -0.63 | −91% | 8 | 2 |
| TTM | -0.43 | 20 | 4 |
Ratings & facts
RS Rating99 ▲3
Days at RS 90+1
Setup checks3 / 3
EPS chg, last qtr+53%
EPS accelerating3 qtrs ✓
Sales chg, last qtr−100%
P/E (last 4 qtrs)–
Mkt cap$924.8M
Off 52-wk high-0.2%
Quarterly earnings
Latest filing: 10-Q, 2026-08-10Mar ’24FQ1 ’24
Jun ’24FQ2 ’24
Sep ’24FQ3 ’24
Dec ’24Q4FQ4 ’24
Mar ’25FQ1 ’25
Jun ’25FQ2 ’25
Sep ’25FQ3 ’25
Dec ’25Q4FQ4 ’25
Mar ’26FQ1 ’26
Jun ’26FQ2 ’26
EPS
EPS
−$0.02
−$0.14
−$0.25
$0.09
−$0.20
−$0.19
−$0.15
−$0.08
−$0.11
−$0.09
% chg
–
–
–
–
−900%
−36%
+40%
−189%
+45%
+53%
Sales
15.7M
756,000
1.5M
25.3M
142,000
224,000
159,000
34,000
422,000
0
% chg
–
–
–
–
−99%
−70%
−89%
−100%
+197%
−100%
Filed
05/08
08/07
11/06
02/27
05/08
08/07
11/06
03/05
05/07
08/10
EPS growth ≥ 25%0–25%fallingno comparison
Source: SEC EDGAR 10-Q and 10-K filings, loaded the first time a stock is opened and refreshed daily. Q4 = full year minus the first three quarters. Growth from a loss is measured against the size of the loss (−$1 → $2 = +300%). Analyst estimates are not in EDGAR.